Curaleaf HoldingsCURLF +0.69%67 Net-Net Working Capital is $-6.57 as of Mar. 2026. GuruFocus rates CURLF with a GF Score™ of 67/100 and a GF Value™ of $7.98 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 414 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 241545.65% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Curaleaf Holdings's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $-6.57.
The industry rank for Curaleaf Holdings's Net-Net Working Capital or its related term are showing as below:
CURLF's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.75 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Curaleaf Holdings (OTCPK:CURLF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Curaleaf Holdings Net-Net Working Capital Related Terms
Curaleaf Holdings Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CURLF vs ZTS, UTHR: Net-Net Working Capital Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $-6.57 mean?
Curaleaf Holdings (CURLF) has a Net-Net Working Capital of $-6.57 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Curaleaf Holdings According to the industry distribution chart, Curaleaf Holdings ranks #999999 out of 414 companies in the Drug Manufacturers industry.
Is Curaleaf Holdings' Net-Net Working Capital too high?
Curaleaf Holdings' current Net-Net Working Capital is $-6.57. Based on the distribution chart, Curaleaf Holdings ranks #999999 out of 414 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curaleaf Holdings has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Net-Net Working Capital compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #999999 out of 414 companies for Net-Net Working Capital. This places Curaleaf Holdings in the lower half of its industry. The industry median Net-Net Working Capital is 7.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 7.75, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Curaleaf Holdings For the Drug Manufacturers industry, the median Net-Net Working Capital is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Net-Net Working Capital is $-6.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.98, compared to a current price of $9.47 — trading 18.6% above its estimated fair value. The current Net-Net Working Capital is $-6.57. Curaleaf Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Net-Net Working Capital is $-6.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.47 is trading 18.6% above its estimated GF Value™ of $7.98.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
Net-Net Working Capital: $-6.57
GF Value™: $7.98 vs. price of $9.47 (18.6% above fair value)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
67GF Score
Get the complete analysis for CURLF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
